No reduced serum serotonin levels in patients with post-acute sequelae of COVID-19.
Biomarker
Chronic fatigue syndrome
PASC
SARS-CoV-2
Serum serotonin
Journal
Infection
ISSN: 1439-0973
Titre abrégé: Infection
Pays: Germany
ID NLM: 0365307
Informations de publication
Date de publication:
02 Oct 2024
02 Oct 2024
Historique:
received:
09
07
2024
accepted:
14
09
2024
medline:
2
10
2024
pubmed:
2
10
2024
entrez:
2
10
2024
Statut:
aheadofprint
Résumé
Approximately 10-20% of patients previously infected with SARS-CoV-2 experience post-acute sequelae of COVID-19 (PASC), presenting with fatigue and neurocognitive dysfunction along various other symptoms. Recent studies suggested a possible role of a virally induced decrease in peripheral serotonin concentration in the pathogenesis of PASC. We set out to verify this finding in an independent and well-defined cohort of PASC patients from our post-COVID-19 outpatient clinic. We performed a retrospective case-control study including 34 confirmed PASC patients and 14 healthy controls. Clinical assessment encompassed physician examination as well as questionnaire based evaluation. Eligibility required ongoing symptoms for at least 6 months post-PCR-confirmed infection, relevant fatigue (CFS ≥ 4), and no other medical conditions. Serum serotonin was determined by LC-MS/MS technique. Serum serotonin levels in PASC patients did not significantly differ from healthy controls. Most subjects had normal serotonin levels, with no subnormal readings. Subgroup analyses showed no significant differences in serotonin levels based according to predominant fatigue type, high overall fatigue score or depression severity. We postulate that peripheral serotonin is no reliable biomarker for PASC and that it should not be used in routine diagnostic. Therapy of PASC with serotonin-reuptake inhibitors or tryptophane supplementation should not be based solely on the assumption of lowered serotonin levels.
Identifiants
pubmed: 39356444
doi: 10.1007/s15010-024-02397-5
pii: 10.1007/s15010-024-02397-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Peter RS, Nieters A, Kräusslich HG, et al. Post-acute sequelae of covid-19 six to 12 months after infection: population based study. BMJ. 2022;379: e071050. https://doi.org/10.1136/bmj-2022-071050 .
doi: 10.1136/bmj-2022-071050
pubmed: 36229057
Butzin-Dozier Z, Ji Y, Deshpande S, et al. SSRI Use During Acute COVID-19 Infection Associated with Lower Risk of Long COVID Among Patients with Depression. Published online February 6, 2024:2024.02.05.24302352. https://doi.org/10.1101/2024.02.05.24302352
Sidky H, Hansen KA, Girvin AT, et al. Assessing the effect of selective serotonin reuptake inhibitors in the prevention of post-acute sequelae of COVID-19. Comput Struct Biotechnol J. 2024;24:115–25. https://doi.org/10.1016/j.csbj.2023.12.045 .
doi: 10.1016/j.csbj.2023.12.045
pubmed: 38318198
pmcid: 10839808
Wong AC, Devason AS, Umana IC, et al. Serotonin reduction in post-acute sequelae of viral infection. Cell. 2023;186:4851-4867.e20. https://doi.org/10.1016/j.cell.2023.09.013 .
doi: 10.1016/j.cell.2023.09.013
pubmed: 37848036
pmcid: 11227373
Sadlier C, Albrich WC, Neogi U, et al. Metabolic rewiring and serotonin depletion in patients with postacute sequelae of COVID-19. Allergy. 2022;77:1623–5. https://doi.org/10.1111/all.15253 .
doi: 10.1111/all.15253
pubmed: 35150456
Rao ML, Gross G, Strebel B, et al. Circadian rhythm of tryptophan, serotonin, melatonin, and pituitary hormones in schizophrenia. Biol Psychiat. 1994;35:151–63. https://doi.org/10.1016/0006-3223(94)91147-9 .
doi: 10.1016/0006-3223(94)91147-9
pubmed: 7909693
Korse CM, Buning-Kager JCGM, Linders TC, et al. A serum and platelet-rich plasma serotonin assay using liquid chromatography tandem mass spectrometry for monitoring of neuroendocrine tumor patients. Clin Chim Acta. 2017;469:130–5. https://doi.org/10.1016/j.cca.2017.04.001 .
doi: 10.1016/j.cca.2017.04.001
pubmed: 28385629